William Mansfield

Will is Consultant and Customer Success Manager at PatentSight. He has strong knowledge of Electronics, including Solar Power. He is a power user of PatentSight BI and loves to share his knowledge as well as being a partner for discussions around patent analyses.

Recent Posts

China in Rare Earth Elements - top supplier, major patent developer, yet portfolio strength still a concern

Posted by William Mansfield on Sep 4, 2019 10:33:56 AM

From recent news reports it became clear that China accounts for almost 90% of the world’s production and supply of the so-called Rare Earth Elements (REE). These are a group of 17 elements that are not commonly found in the earth's surface. For e.g. Scandium, one of the rare earth elements, is heavily used in manufacturing parts for the aerospace industry. Similarly, these elements have varied and extremely specific uses, for which, at least for the time-being, no viable substitutes can be sourced. We used our excellent patent database and scientifically proven metrics to analyze the current situation around rare earth elements from a patent quality point of view to identify possible opportunities and threats in this business.

Read More

Tags: Technology, Science, Patent Analysis, Patent Valuation, Patent Asset Index, Patent Quality, Rare earth metals, China, USA, rare earth elements


Patent portfolio evolution within the payment card industry - The American Express example

Posted by William Mansfield on Aug 29, 2019 8:38:38 AM

The payment card industry (PCI) encompasses organizations and institutions that store, process and transmit cardholder data, with major brands such as American Express, Mastercard Inc, Visa Inc and others. In this blog post, we provide insights into the competitive environment of the PCI with a focus on American Express, with regard to patent holdings. Using our industry-proven, scientifically validated Patent Asset Index™, we find that the company has fallen behind its competitors despite a constant patent portfolio development.

Read More

Tags: Deep-dive, Future, trend scouting, solutions provider, American Express, card technology


Israeli Innovation Leader - A patent analysis

Posted by William Mansfield on Mar 12, 2019 9:32:59 AM

Recently, we applied the PatentSight Patent Asset Index methodology to gain a new insight into which of Israel’s research bodies are leading in innovation. The index assesses the strength of an organization’s patent portfolio in terms of quality of patents held measured by TechnologyRelevance™ and Market Coverage ™. So, what did we find?

 

Read More

Tags: Science, Patent Analysis, Innovation, Patent Asset Index


Samsung’s runaway lead in foldable displays by Patent Asset Index™

Posted by William Mansfield on Mar 4, 2019 10:54:00 AM

End of February 2019 Samsung revealed its long rumored smart phone with a foldable display, the first of its kind to have an official release date. A number of players have been rumored to be working on such devices, however Samsung’s combination of in-house smartphone and display technologies may have led to it being first to market.

A closer look at the innovation landscape and the qualitative strength of the patent portfolios in the field of foldable smartphone technology shows the enormous lead Samsung has and the areas in which Apple has to catch up.

Read More

Tags: Technology, Patent Analysis, Innovation, Patent Asset Index


Patent analysis reveals opportunities and concerns around the Bristol-Myers Squibb/Celgene merger

Posted by William Mansfield on Feb 25, 2019 4:46:01 PM

In January of this year, U.S. pharmaceutical manufacturers Bristol-Myers Squibb (BMS) and Celgene Corporation announced they had entered into a definitive merger agreement for BMS to acquire Celgene.

The stated aim of the merger is to create ‘a premier innovative biopharma company’ with a particular focus on building an expanded offering in the cancer and immunotherapy space. If completed, the transaction is expected to cost $74 billion in a cash and stock deal, whereby Celgene shareholders will receive 1.0 BMS share as well as $50 in cash for each share of Celgene.

Our analysis of the two firms’ respective patent portfolios provides insight into how this merger would affect the U.S. pharma market. For this analysis, we employed our Patent Asset IndexTM methodology, which scientifically assesses patent families against Key Performance Indicators of Technology RelevanceTM and Market CoverageTM.

Read More

Tags: Science, Mergers and Acquisitions, Patent Analysis, Patent Asset Index


Tesla to buy Maxwell Technologies: an important technological edge in the battery market for electric cars

Posted by William Mansfield on Feb 7, 2019 9:47:00 AM

With the acquisition of Maxwell Technologies, Tesla expands its patent portfolio and includes technologies that may lead to a major advantage in the future technology of efficient batteries for electric cars. The company is a specialist in the field of energy storage. For Tesla this can mean a leap forward in the highly competitive field of battery technology for electric cars. A closer look at this acquisition scenario shows us in which technology areas Maxwell can significantly complement Tesla's patent portfolio.

Read More

Tags: Technology, Mergers and Acquisitions, Patent Analysis, Innovation, Patent Asset Index


Application fields and active protection - A closer look at the top 20 Universities and Research centers

Posted by William Mansfield on Jan 11, 2019 3:53:59 PM

For a study commissioned by IAM, PatentSight has taken a closer look at the patenting activity of leading universities and research centers based on the Patent Asset IndexTM.

Read More

Tags: Technology, Science, Innovation, Patent Asset Index


The Transformation into the New Takeda

Posted by William Mansfield on Apr 27, 2018 3:51:06 PM

In 2011 faced with “the impending loss of patent protection on certain leading products”, the Takeda Pharmaceutical Company unveiled its mid-term plan to achieve sustainable growth. Over the 10 years prior to this Takeda had pruned its patent portfolio significantly from over 3500 patent families in the year 2000 to less than 1900 in 2008, saving the company millions of dollars over the lifetime of these patents. Whilst such cost saving measures would have reduced the company’s liabilities, this alone would have not ensured long-term prosperity. Enter the “New Takeda”.

Read More

Tags: Mergers and Acquisitions


Becton Dickinson secures itself as a healthcare innovation leader with Bard acquisition

Posted by William Mansfield on Apr 12, 2018 7:41:00 AM

Becton Dickinson’s 24bn USD acquisition of U.S. peer C.R. Bard, as reported by Reuters, has secured its position as one of the top 10 global healthcare companies in terms of both revenue and innovation. Although the combined company will still wield a smaller patent portfolio than the industry giants, the average quality of the portfolio is significantly above average, surpassed only by Johnson & Johnson. This high quality means the combined entity now has 6th strongest portfolio in the field of healthcare, as defined by ip-search a division of the CHPTO, out of the top 30 medical device manufacturers, by annual revenue reported in MPO magazine.

Read More

Tags: Mergers and Acquisitions, Innovation, Patent Asset Index, Regulation